Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
Earnings Data
Report Date
Jul 29, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.14Last Year’s EPS
-0.06Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 29, 2025
|% Change Since: 29.39%
|Next Earnings Date:Jul 29, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance for Kiniksa Pharmaceuticals in Q1 2025, driven by significant revenue growth for ARCALYST and an increase in prescriber adoption. Despite minor concerns regarding potential manufacturing tariffs and Medicare Part D patient retention, the company's financial outlook remains robust.Company Guidance
In the first quarter of 2025, Kiniksa Pharmaceuticals reported a strong commercial performance driven primarily by its ARCALYST product for recurrent pericarditis, achieving a net product revenue of $137.8 million, a 75% increase from the previous year. This growth was supported by an expansion in the prescriber base, with around 300 new prescribers, and an increase in the average duration of therapy from approximately 27 to 30 months. The positive financial results allowed Kiniksa to revise its ARCALYST net sales guidance upward to $590 million to $605 million for 2025. Additionally, the company is preparing to initiate a Phase II/III clinical trial for KPL-387, with Phase II data expected in 2026. Kiniksa maintains a strong financial position, ending the quarter with a cash balance of $268.3 million, and expects to remain cash flow positive on an annual basis.Strong ARCALYST Revenue Growth
Net product revenue for ARCALYST reached $137.8 million in Q1 2025, a 75% year-over-year increase compared to Q1 2024. The company increased its 2025 net sales guidance from $560-$580 million to $590-$605 million.
Increased Prescriber Base
The number of new prescribers increased by approximately 300 in Q1 2025, one of the highest quarterly increases since launch.
Positive Financial Performance
Kiniksa reported a net income of $8.5 million in Q1 2025 compared to a net loss of $17.7 million in Q1 2024. ARCALYST collaboration profit grew 118% year-over-year to $87.6 million.
Extended Average Duration of Therapy
The average duration of therapy for ARCALYST increased from 27 months to 30 months.
Favorable Medicare Part D Changes
Federal changes to the Medicare Part D program improved patient affordability, leading to a onetime bolus of patients converting to paid therapy at the start of Q1 2025.
---
KNSA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
KNSA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 29, 2025 | $21.47 | $25.88 | +20.54% |
| Feb 25, 2025 | $19.63 | $19.72 | +0.46% |
| Oct 29, 2024 | $27.59 | $23.26 | -15.69% |
| Jul 23, 2024 | $26.29 | $25.20 | -4.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Kiniksa Pharmaceuticals (KNSA) report earnings?
Kiniksa Pharmaceuticals (KNSA) is schdueled to report earning on Jul 29, 2025, TBA Not Confirmed.
What is Kiniksa Pharmaceuticals (KNSA) earnings time?
Kiniksa Pharmaceuticals (KNSA) earnings time is at Jul 29, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KNSA EPS forecast?
KNSA EPS forecast for the fiscal quarter 2025 (Q2) is 0.14.
---